white → yellow1
dose.wiki is still in beta. Entries may contain inaccuracies and/or lack citations. See our docs for more info.
NEP
N-Ethylpentedrone
Ethyl-pentedrone, N-ethylnorpentedrone, α-ethylaminopentiophenone, α-EAPP, α-ethylamino-valerophenone
NEP is a substituted cathinone1 that produces stimulating, euphoric, and mildly entactogenic effects. It first appeared on the research chemical market in 2016 as a contemporary designer drug. Structurally related to pentedrone, it differs by an additional ethyl group on the terminal nitrogen, reportedly making it roughly three times as potent.citation needed NEP is also closely related to N-ethylhexedrone and is noted for its relatively short duration of action.
Dosage & Duration
Dosage
Doses are population estimates that vary widely between individuals.
Threshold~10 mg
Light10-20 mg
Moderate20-40 mg
Strong40-60 mg
Heavy60+ mg
Duration
Onset10-20 minutes
After Effects1-24 hours
Total2.5-4 hours
Subjective Effects
Legacy content. A statistically backed ontology from Mindstate Design Labs is coming soon.
NEP produces a short-acting stimulant experience centered on wakefulness, modest mood enhancement, talkativeness, and restless energy, with a headspace that tends to be scattered rather than focused. Rapid-onset routes can produce a brief euphoric rush, but it is generally weak and subsides within five to ten minutes, and many users experience little more than a fast surge of energy. The most enjoyable effects last roughly 45 to 60 minutes before giving way to plain stimulation, and because euphoria fades faster than the stimulation itself — often declining within two to three doses — the substance is strongly associated with compulsive redosing and extended binges. A small minority of users describe mildly entactogen-like warmth, though far below the intensity of substances like MDMA.
Physical
Stimulation at common doses is described as relatively smooth with minimal bodyload. Heavier use frequently brings a racing or pounding heart, palpitations, restlessness, muscle tension, jaw clenching, and cold extremities from vasoconstriction. Insufflation causes nasal pain and irritation that ranges from a few minutes of burning to severe inflammation, persistent sneezing, and occasional bleeding depending on the batch and level of use.
Cardiovascular
Cardiovascular effects are minor at common doses but become prominent with heavier use.
Stimulation
Uncomfortable
Insufflation is inconsistently but sometimes severely irritating, ranging from brief burning to intense pain, inflammation, persistent sneezing for 30-60 minutes, and nose bleeding depending on the batch.
Cognitive
The headspace is energetic and talkative but characteristically scatterbrained, with frequent task-switching that undermines its functional potential; clearheaded mental work is usually impaired even at lower doses. Anxiety is absent or mild at common doses but escalates sharply with large doses and prolonged redosing, potentially progressing to paranoia, delusions, or psychosis when combined with multiday binges and sleep deprivation.
Emotional
Minor to moderate mood enhancement is more common than true euphoria, and the emotional tone deteriorates quickly with redosing and heavy use.
Enhancements
Psychosis
Psychotic effects are associated with large amounts over multiday periods combined with severe sleep deprivation, and appear to onset faster than with classic stimulants.
Suppressions
Visual
Visual effects are essentially absent at common doses and emerge primarily as impairments during heavy use, binges, and sleep deprivation.
Pharmacology
Pharmacodynamics
NEP is believed to act primarily as a norepinephrine-dopamine reuptake inhibitor, increasing the accumulation of these monoamines in the brain.citation needed One study has characterized it as a serotonin-norepinephrine-dopamine reuptake inhibitor with very poor affinity for the serotonin transporter, suggesting that its activity is heavily biased toward dopamine and norepinephrine. The structurally similar cathinone pentedrone has been shown to function as a reuptake inhibitor rather than a monoamine releaser, which may also apply to NEP, though interactions with additional receptor sites have not been ruled out.
Pharmacokinetics
There have been no studies on the pharmacokinetic profile of NEP and the metabolism of NEP is unknown.
Metabolitesnone documented yet
Dangerous
Highest riskThese combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
Tolerance
Tolerance timelines are rules of thumb, not exact schedules, and vary widely between individuals and use patterns.
Full Tolerance
With sustained repeated NEP use, tolerance may develop across many effects. Euphoria can begin declining within 2-3 doses, and continued use may mainly extend wakefulness and intoxication while positive effects become shorter and weaker.
Baseline Reset
1-2 weeks
Half Tolerance
3-7 days
Cross Tolerance
Dopaminergic stimulants
Harm Potential
Addiction & Dependence
Psychological
ModerateModerately addictive with a high potential for abuse and capable of causing psychological dependence.citation needed Compulsive redosing is a common pattern, with users entering an almost automatic state of redosing regardless of whether the effects remain pleasant. The short duration contributes to repeated administration, and once use deviates from planned limits, escalation is common.
Physical
LowWhen addiction has developed, cravings and withdrawal effects may occur upon cessation. Physical dependence appears less prominent than psychological dependence, with sources primarily emphasizing compulsive use patterns rather than severe physical withdrawal.
Toxicity
Cardiovascular
Increases heart rate significantly compared to other stimulants, even at low doses, along with elevated blood pressure and occasional abnormal heartbeat;citation needed acute myocardial infarction, arrhythmias, and stroke are presumed possible with large overdoses, though no formal data exists.
Nasal/Respiratory
Intranasal use causes nasal discomfort and irritation; heavy use can produce significant nasal inflammation and occasionally bleeding, though severity varies substantially between batches.
Psychosis Risk
Extended use at high dosages can result in stimulant psychosis presenting with paranoia, hallucinations, and delusions.citation needed Compared to classic stimulants, paranoia, visual distortions, and unusual thinking appear to have faster onset, potentially becoming apparent within one day of heavy use. Sleep deprivation significantly increases risk. The most concerning effects can almost always be prevented by avoiding sleep deprivation and limiting use duration.
Seizure Risk
No case reports of NEP-induced seizures exist, but like other stimulants it likely has seizure-inducing capacity. Best avoided in those with preexisting seizure disorders.
History & Culture
N-Ethylpentedrone emerged on the online research chemical market during the mid-2010s, with documented user experience reports beginning to appear around 2016. The compound represents a generation of synthetic cathinone derivatives developed as functional and structural alternatives to earlier…
Legality
International
NEP is not listed under the 1961 Single Convention on Narcotic Drugs. It is not listed under the 1971 Convention on Psychotropic Substances. It is not listed under the 1988 Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances.
By Country
Illegal22
ArgentinaIllegalLa N-etilpentedrona figura en el Anexo I del Decreto N.º 122/2026, que sustituyó el Anexo I del Decreto N.º 560/2019 y entró en vigor el 3 de marzo de 2026. La inclusión la califica como estupefaciente para el artículo 77 del Código Penal. La producción, preparación, comercio y tenencia no autorizados de estupefacientes están penados por la Ley N.º 23.737.
AustraliaIllegal (analog/blanket ban)N-Ethylpentedrone (NEP) is captured by the cathinones group entry in Schedule 9 of the Therapeutic Goods (Poisons Standard—June 2026) Instrument 2026. Schedule 9 classifies it as a prohibited substance and states that its manufacture, possession, supply or use should be prohibited by law except for approved medical or scientific research, analytical, teaching or training purposes. The current Poisons Standard commenced on 1 June 2026.
AustriaIllegal (analog/blanket ban)Neue-Psychoaktive-Substanzen-Verordnung (NPSV), Anlage II Nr. 3, issued under the Neue-Psychoaktive-Substanzen-Gesetz (NPSG)678
NEP (2-(ethylamino)-1-phenylpentan-1-one) is covered as an amino-phenyl-ethanone compound by Annex II, item 3, of Austria’s New Psychoactive Substances Regulation. The annex covers every compound derived from that chemical basic structure. Under the New Psychoactive Substances Act, for-profit production, import, export, supply, or procurement for another person’s psychoactive use is punishable by up to two years’ imprisonment. The current Annex II text has applied since 19 April 2024.
BelgiumIllegal (analog/blanket ban)Arrêté royal du 6 septembre 2017 réglementant les substances stupéfiantes et psychotropes, annexe IVa910
N-Ethylpentedrone is controlled in Belgium as a cathinone derivative under annex IVa to the Royal Decree of 6 September 2017 regulating narcotic and psychotropic substances. The annex's generic 2-amino-1-phenylpropan-1-one definition covers its N-ethyl, propyl-side-chain, and unsubstituted-phenyl structure. Since 26 September 2017, importing, exporting, transporting, manufacturing, producing, possessing, selling, supplying, or acquiring the substance requires authorization; authorizations are limited to scientific or medical purposes, and violations are punishable under the 1921 drugs law.
BrazilIllegalNEP (N-ethylpentedrone; 2-(ethylamino)-1-phenylpentan-1-one) is expressly listed as alfa-EAPP in Lista F2 of Anexo I to Portaria SVS/MS nº 344/1998. Lista F2 forms part of Brazil’s list of substances of prohibited use, so production, manufacture, import, export, commerce, and use are prohibited except for authorised medical or scientific research.
ChinaIllegalThree-department announcement on adding 16 substances to the Non-medical Narcotic Drugs and Psychotropic Substances Directory (dated 2026-06-17; effective 2026-07-01); Non-medical Narcotic Drugs and Psychotropic Substances Directory (2025), as supplemented by that 2026 addition; Regulation on the Control of Narcotic Drugs and Psychotropic Substances (2024 revision effective 2025-01-20), Articles 3, 4, 82 and 87; Drug Control Law, Articles 2, 21 and 22; Criminal Law, Articles 347, 348 and 357; Public Security Administration Punishments Law (2025), Article 84 (effective 2026-01-01).1516171819202122232425
NEP is controlled under national drug legislation and was expressly added to the national non-medical narcotic and psychotropic directory effective 2026-07-01. The current directory reproduction identifies the exact Chinese and English chemical names, CAS 779974-89-9 and abbreviation NEP. Ordinary unauthorized production, commerce, use, storage and transport are prohibited under current Regulation Article 4, while unlawful possession/provision and smuggling are separately prohibited by the Drug Control Law. Criminal and administrative consequences depend on conduct, quantity, intent, authorization and case facts; the Supreme People's Court catch-all rules set no NEP-specific quantity threshold.
Czech RepublicIllegalGovernment Regulation No. 463/2013 Coll., on lists of addictive substances, Annex 4; Act No. 167/1998 Coll., on addictive substances, §§ 2 and 42627
NEP is listed as N-ethylnorpentedron (N-ethylpentedron) in List No. 4 of the Czech Government Regulation on lists of addictive substances, which classifies it as a psychotropic substance. The Act on Addictive Substances requires a handling permit for addictive substances; substances in List No. 4 may be used only for the limited research, scientific, and very limited therapeutic purposes specified in that permit. Accordingly, unauthorized acquisition, storage, production, or supply of NEP is prohibited.
FinlandIllegalValtioneuvoston asetus huumausaineina pidettävistä aineista, valmisteista ja kasveista (543/2008), Liite I, as amended by 651/2026282930
NEP is a narcotic drug in Finland. It is listed as N-etyylinorpentedroni (NEP) in Annex I to the Government Decree on substances, preparations and plants regarded as narcotic drugs; the current entry took effect on 10 July 2026. Under the Narcotics Act, production, manufacture, import, export, transport, distribution, trade, handling, possession and use of narcotic drugs are prohibited except as separately provided by law.
FranceIllegal (analog/blanket ban)N-Ethylpentedrone (NEP) is classified as a narcotic in Annexe IV of the Arrêté du 22 février 1990 through the generic class for cathinone-derived molecules bearing an alkyl substituent at position 3 and an alkyl, dialkyl, or cyclic substituent on nitrogen. The classification covers its salts and stereoisomers; unauthorized narcotic-drug conduct is subject to France's narcotics-control law.
GermanyIllegal (analog/blanket ban)N-Ethylpentedrone (NEP) is covered by Stoffgruppe Nr. 1 in Anlage 1 to Germany's Neue-psychoaktive-Stoffe-Gesetz as a cathinone derived from 2-phenethylamine. The Act prohibits trading in, placing on the market, manufacturing, importing, exporting, transiting, acquiring, possessing, or administering covered substances to another person, subject to its statutory exceptions.
IrelandIllegal (analog/blanket ban)Misuse of Drugs Act 1977 (Controlled Drugs) (Designation) Order 2022 (S.I. No. 211 of 2022), Schedule 1, paragraph 1(b)3839
Ireland designates N-ethylpentedrone (NEP) as a Schedule 1 controlled drug through the cathinone analogue definition in the Misuse of Drugs Act 1977 (Controlled Drugs) (Designation) Order 2022. The definition covers the substance's alkyl substitution at the propanone side-chain and ethyl substitution at nitrogen. Manufacture, production, preparation, sale, supply, distribution and possession of Schedule 1 drugs are unlawful except for research or the other specified purposes, subject to the applicable licensing provisions.
IsraelIllegal (analog/blanket ban)NEP (N-ethylpentedrone; 2-(ethylamino)-1-phenylpentan-1-one) is controlled in Israel as a structural derivative of cathinone under the First Schedule to the Dangerous Drugs Ordinance. The Schedule defines a structural derivative as a substance in which one or more chemical groups have been substituted or removed from the structure of a listed substance, and the cathinone entry includes its structural derivatives unless expressly excluded. Possession, production, and supply of a dangerous drug are prohibited except as authorized under the Ordinance.
JapanIllegal (analog/blanket ban)Ordinance Specifying Designated Drugs under the Pharmaceuticals and Medical Devices Act, Article 1, item 361; Pharmaceuticals and Medical Devices Act, Article 76-44344
Designated as a controlled substance under national drug control legislation. Possession, distribution, and manufacturing are prohibited.
NetherlandsIllegal (analog/blanket ban)NEP falls within Lijst IA of the Opiumwet as a cathinone-based substance derived from 2-fenethylamine: the statutory definition includes the cathinone base structure, an alkyl substituent on nitrogen, and beta-keto derivatives. The Opiumwet prohibits importing or exporting, preparing, processing, selling, supplying, transporting, possessing, and manufacturing a substance in a Lijst IA substance group or a preparation containing it. The Lijst IA regime entered into force on 1 July 2025.
NorwayIllegalForskrift om narkotika (narkotikaforskriften), Narkotikalisten, as amended by FOR-2024-02-29-3574849
NEP is listed as N-etylpentedron (NEP) in Norway’s Narkotikalisten and has been prohibited since 29 February 2024. The Narkotikaforskriften prohibits the manufacture, acquisition, sale, import, export, storage, possession and use of substances in the list that refer to section 5, including NEP.
PortugalIllegalN-Ethylpentedrone (NEP) is listed in Table II-A of Portugal's Decree-Law No. 15/93 by Law No. 19-F/2026. The amendment takes effect on 9 May 2026. The substance is subject to the legal regime for trafficking and consumption of narcotic drugs and psychotropic substances.
RussiaIllegalGovernment Decree of the Russian Federation No. 681 of 30 June 1998, ‘On approval of the list of narcotic drugs, psychotropic substances and their precursors subject to control in the Russian Federation’53
NEP (N-ethylpentedrone) is a cathinone derivative and falls within the List I entry for cathinone and its derivatives in Government Decree No. 681. List I covers narcotic drugs whose circulation is prohibited in the Russian Federation, so unauthorised possession, manufacture, and sale are prohibited under Russia’s drug-control framework.
SingaporeIllegalNEP is N-ethylpentedrone, expressly identified as 2-(ethylamino)-1-phenylpentan-1-one (also called α-ethylaminopentiophenone). It is a Class A controlled drug; the First Schedule also extends coverage to applicable stereoisomers, salts, and preparations or products containing the scheduled substance.
SpainIllegalOrden SND/362/2026, de 13 de abril, artículo único, que modifica el anexo 1 del Real Decreto 2829/1977575859
NEP is listed as N-etilnorpentedrona in List II of Annex 1 to Spain's psychotropic-substances regime under Orden SND/362/2026. The order took effect on 22 April 2026 and applies the List II control measures and criminal penalties to NEP, including its stereochemical variants, racemates, and salts where they can exist. Manufacturers, importers, exporters, distributors, and dispensers must comply with the requirements applicable to List II psychotropic substances.
SwitzerlandIllegal (analog/blanket ban)Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien (Betäubungsmittelverzeichnisverordnung, BetmVV-EDI)6364
N-Ethylpentedrone (NEP) is covered as a cathinone by the generic Cathinone class in Verzeichnis e of the Swiss Betäubungsmittelverzeichnisverordnung. It is therefore subject to Swiss controls as a raw material or product with presumed narcotic-like effects; that class exempts industrial use by a business holding the required Verzeichnis-e controlled-substances operating licence from the controls in Chapters 5 and 6 of the Betäubungsmittelkontrollverordnung, with no import or export permit required for quantities up to 100 g.
United KingdomIllegal (analog/blanket ban)N-Ethylpentedrone (NEP) is a Class B controlled drug under the Misuse of Drugs Act 1971 because it falls within the Act's generic cathinone definition for compounds structurally derived from 2-amino-1-phenyl-1-propanone. The generic control has applied since 16 April 2010; unauthorised possession, production, supply, importation, and exportation of a controlled drug are unlawful under the Act, subject to its statutory exceptions, regulations, and licences.
Controlled / restricted1
CanadaNot explicitly scheduledWhile not individually listed, NEP may be treated as a Schedule I substance under the Controlled Drugs and Substances Act due to provisions banning derivatives of amphetamine.14
Not scheduled2
United StatesNot scheduledNot federally scheduled under the Controlled Substances Act. However, possession or distribution intended for human consumption could potentially be prosecuted under the Federal Analogue Act due to structural and pharmacological similarities to pentedrone, which is a Schedule I controlled substance.69
By state
Across the 50 states, D.C., and the permanent territories, most jurisdictions treat NEP consistently with federal control; listed entries record independently verified differences in state classification or coverage.
AlabamaIllegalAla. Admin. Code r. 420-7-2, Appendix, Schedule I70
Alabama expressly places N-ethylpentedrone in Schedule I under its systematic chemical name and synonyms. Possession and distribution are therefore governed by Alabama's controlled-substance offenses rather than depending on the federal analogue test.
CaliforniaRestrictedCal. Health & Safety Code § 11375.571
California prohibits possession for sale, sale, distribution, and specified possession of synthetic stimulant compounds defined by a cathinone structural formula. NEP falls within the covered cathinone-derived class, although California regulates this class in a dedicated offense rather than listing every member in the ordinary schedules.
District of ColumbiaIllegalD.C. Code § 48-902.04(5)(A)(i)72
The District of Columbia controls NEP as a Schedule I synthetic cathinone through a structural class provision. The direct local schedule classification is materially different from the federal baseline's conditional analogue treatment.
FloridaIllegalFla. Stat. § 893.03(1)(c)73
Florida's Schedule I includes substituted cathinones through a broad structural definition. NEP is a covered substituted cathinone, so Florida controls it directly despite the absence of a federal NEP schedule entry.
GeorgiaIllegalO.C.G.A. § 16-13-25(12)74
Georgia places substituted cathinones in Schedule I under a structural-class definition. NEP is directly covered by that provision, creating state Schedule I treatment rather than contingent federal-analogue treatment.
HawaiiIllegalHaw. Rev. Stat. § 329-14(d)75
Hawaii includes substituted cathinones in Schedule I by structural definition. NEP falls within that class and is directly scheduled under Hawaii law, independent of the federal analogue criteria.
IdahoIllegalIdaho Code § 37-270576
Idaho's Schedule I controls substituted cathinones using a structural-class definition. NEP is consequently controlled under Idaho law even though it is not individually scheduled at the federal level.
IllinoisIllegal720 ILCS 570/204(h)77
Illinois places substituted cathinones in Schedule I through a detailed structural definition. NEP falls within that class and is directly controlled by Illinois law rather than solely through possible federal analogue prosecution.
IndianaIllegalInd. Code § 35-48-2-478
Indiana includes substituted cathinones in Schedule I under a structural formula and substitution rules. NEP is within the covered class, resulting in direct state scheduling rather than conditional federal-analogue treatment.
MontanaIllegalMont. Code Ann. § 50-32-22279
Montana places the statutory substituted-cathinone class in Schedule I. N-Ethylpentedrone is within that controlled class and is prohibited as a Schedule I dangerous drug in Montana.
North CarolinaIllegalN.C. Gen. Stat. § 90-89(5)(j)80
North Carolina places substituted cathinones in Schedule I. N-Ethylpentedrone falls within the statute's 2-amino-1-phenyl-1-propanone structural class because it has an alkyl substitution at the nitrogen atom, so it is controlled under state law.
PennsylvaniaIllegal35 P.S. § 780-104(1)81
Pennsylvania Schedule I controls the statutory substituted-cathinone class. N-Ethylpentedrone is a substituted cathinone within that class and is prohibited as a Schedule I controlled substance in Pennsylvania.
South CarolinaIllegalS.C. Code Ann. § 44-53-190(F)(4)82
South Carolina places substituted cathinones in Schedule I. N-Ethylpentedrone has the nitrogen alkyl substitution covered by the statute's structural definition and is prohibited as a Schedule I controlled substance.
TexasIllegalTexas Controlled Substances Act, Tex. Health & Safety Code § 481.10383
Texas classifies NEP as a Penalty Group 2 controlled substance through its structural definition of synthetic cathinones. This direct state classification does not depend on proving the federal analogue criteria in an individual case.
VirginiaIllegalVirginia Drug Control Act, Va. Code Ann. § 54.1-3446(3)84
Virginia expressly lists N-ethylpentedrone as a Schedule I controlled substance. The named listing creates direct state control rather than the federal baseline's conditional analogue treatment.
West VirginiaIllegalW. Va. Code § 60A-2-204(h)85
West Virginia controls NEP in Schedule I through its synthetic-cathinone structural class. The class covers the compound's cathinone scaffold, acyclic alkyl substitution, and N-alkyl substitution, creating categorical state control rather than conditional analogue treatment.
WisconsinIllegalWis. Stat. § 961.14(7)(L)86
Wisconsin controls NEP in Schedule I through its synthetic-cathinone structural class. The class covers the compound's cathinone scaffold, acyclic alkyl substitution, and N-alkyl substitution, creating categorical state control rather than conditional analogue treatment.
ItalyTable 1Added to Table 1 of psychotropic substances on December 29, 2020.42 As a Table 1 substance, it is subject to the strictest controls under Italian drug legislation.citation needed
References
Source Pages
Citations
- Alexandre Barcia Godoi, Daziani G, Taoussi O, Berardinelli D, Bambagiotti G, Huestis MA, Busardò FP, & Carlier J. (2024). Metabolic Stability and Metabolite Identification of N-Ethyl Pentedrone Using Rat, Mouse and Human Liver Microsomes. https://doi.org/10.3390/pharmaceutics160202571
- Decreto N.º 122/2026, Anexo I (sustituye el Anexo I del Decreto N.º 560/2019). argentina.gob.ar (n.d.). https://www.argentina.gob.ar/normativa/nacional/decreto-122-2026-423520/texto1
- Decreto N.º 122/2026, Anexo I (sustituye el Anexo I del Decreto N.º 560/2019). argentina.gob.ar (n.d.). https://www.argentina.gob.ar/normativa/nacional/ley-23737-138/actualizacion1
- Therapeutic Goods (Poisons Standard—June 2026) Instrument 2026. legislation.gov.au (n.d.). https://www.legislation.gov.au/F2026L00633/latest/text1
- Therapeutic Goods (Poisons Standard—June 2026) Instrument 2026. api.prod.legislation.gov.au (n.d.). https://api.prod.legislation.gov.au/v1/titles('F2026L00633')1
- Neue-Psychoaktive-Substanzen-Verordnung (NPSV), Anlage II Nr. 3, issued under the Neue-Psychoaktive-Substanzen-Gesetz (NPSG). ris.bka.gv.at (n.d.). https://www.ris.bka.gv.at/eli/bgbl/II/2024/106/202404181
- Neue-Psychoaktive-Substanzen-Verordnung (NPSV), Anlage II Nr. 3, issued under the Neue-Psychoaktive-Substanzen-Gesetz (NPSG). ris.bka.gv.at (n.d.). https://www.ris.bka.gv.at/Dokumente/BgblAuth/BGBLA_2024_II_106/Anlagen_0001_BA9813D3_0B74_48C4_93B4_C711A2708880.pdf1
- Neue-Psychoaktive-Substanzen-Verordnung (NPSV), Anlage II Nr. 3, issued under the Neue-Psychoaktive-Substanzen-Gesetz (NPSG). ris.bka.gv.at (n.d.). https://www.ris.bka.gv.at/Dokumente/Bundesnormen/NOR40134447/NOR40134447.html1
- Arrêté royal du 6 septembre 2017 réglementant les substances stupéfiantes et psychotropes, annexe IVa. ejustice.just.fgov.be (n.d.). https://www.ejustice.just.fgov.be/eli/arrete/2017/09/06/2017031231/justel1
- Arrêté royal du 6 septembre 2017 réglementant les substances stupéfiantes et psychotropes, annexe IVa. ejustice.just.fgov.be (n.d.). https://www.ejustice.just.fgov.be/mopdf/2017/09/26_1.pdf#page=1461
Further Reading
CFSRE: NEP monograph
Drug Intelligence Bulletin: Rising Trend of NEP (2023)
Forensic fatal cases (2025)
Journal of Analytical Toxicology case series
Journal of Analytical Toxicology: NEP case series- Metabolic profile NEH/NEP/4-CMC (2024)
- Metabolic profile: NEH, NEP, and 4-CMC (2024)
- PMC: Metabolic stability and metabolite identification of NEP
PMC: Toxicological analysis of cathinone intoxications- PubChem: N-Ethylpentedrone (CID 132886199)
- PubMed: Human hepatocyte elimination half-life study (38399311)
Reddit r/ResearchChemicals: NEP experience report (2019)- Reddit r/ResearchChemicals: NEP tips and facts (2018)
ResearchGate: Oral-fluid pharmacokinetics table- ScienceDirect: Repeated administration of NEP induces aggression in mice (2022)
UNODC: Early Warning Advisory on NPS- UNODC: ICE 2024/1 Summary - N-Ethylpentedrone listings
Article Status
Step 1 · Automated synthesisAn autonomous workflow built by Josie Kins compiled this article's foundation from information published across the web.
- Step 2 · First-pass review
A first pass manual review and edit of article prose and copy has been performed by subject-matter expert Lyrea. This does not guarantee factual accuracy. An additional human review for each of this article's citations is yet to be performed.
- Step 3 · Citation reviewPending
No one has reviewed this article's citations yet. That second pass checks each claim against the source it cites.
Recent changes7 human edits · latest
Times are UTCNewest first
24 January 2026
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Suggest an edit
Spotted a mistake, an outdated claim, or something missing from the NEP article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.
Wish to give generalised feedback? You can do so here.